Analysis of polymorphism and development of a molecular-genetic system for genotyp-ing by the telomerase reverse transcriptase (TERT) gene

This article explores the genetic variability of the gene that encodes telomerase reverse transcriptase (TERT), which plays a key role in maintaining telomere length and, as a result, genome stability in various eukaryotic species. The study employs a comprehensive approach that combines phylogenetic and bioinformatic analysis with molecular-genetic research methods. The research involved the screening of genetic databases to investigate TERT gene orthologues across organisms belonging to different systematic groups. The TERT gene, which is prevalent in a wide range of eukaryotic biological species, exhibits polymorphisms that have the potential to influence TERT enzyme function and, consequently, animal phenotypes. The primary focus of this study centers on the pig TERT gene, selected as a model organism due to its genetic similarity to humans and its importance as a productive agricultural species. The article explores the exon-intron structure of the TERT gene, analyzing the size of the corresponding transcript and protein product. Furthermore, it provides data on polymorphisms in the pig TERT gene, including missense and synonymous variants. The chromosomal localization of these polymorphisms is characterized and correlated with the domain structure of the TERT enzyme. For the evaluation of the impact of polymorphisms on the structural and functional properties of the TERT enzyme, a molecular-genetic system based on the PCR-RFLP method has been developed. This PCR-RFLP system serves as a basis for subsequent experimental analyses of missense and synonymous variants in population and association studies, allowing for an assessment of the prevalence of these polymorphisms and their significance for animal phenotypes. Given the significance of further laboratory investigation of the pig TERT gene, the developed PCR-RFLP system becomes necessary for the assessment of the functional implications of the polymorphisms within this gene and the potential identification of causative ones among them. The synergy of bioinformatics and molecular-genetic methods in this study lays the groundwork for future impactful research in this field. The presented study holds promise for marker-associated selection, as it opens the way for the use of the TERT gene as a marker in the genetic improvement of agricultural animal species

A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies

Objective: Clinical care of rare and complex epilepsies is challenging, because evidence‐based treatment guidelines are scarce, the experience of many physicians is limited, and interdisciplinary treatment of comorbidities is required. The pathomechanisms of rare epilepsies are, however, increasingly understood, which potentially fosters novel targeted therapies. The objectives of our survey were to obtain an overview of the clinical practice in European tertiary epilepsy centers treating patients with 5 arbitrarily selected rare epilepsies and to get an estimate of potentially available patients for future studies. / Methods: Members of the European Reference Network for rare and complex epilepsies (EpiCARE) were invited to participate in a web‐based survey on clinical practice of patients with Dravet syndrome, tuberous sclerosis complex (TSC), autoimmune encephalitis, and progressive myoclonic epilepsies including Unverricht Lundborg and Unverricht‐like diseases. A consensus‐based questionnaire was generated for each disease. / Results: Twenty‐six of 30 invited epilepsy centers participated. Cohorts were present in most responding centers for TSC (87%), Dravet syndrome (85%), and autoimmune encephalitis (71%). Patients with TSC and Dravet syndrome represented the largest cohorts in these centers. The antiseizure drug treatments were rather consistent across the centers especially with regard to Dravet syndrome, infantile spasms in TSC, and Unverricht Lundborg / Unverricht‐like disease. Available, widely used targeted therapies included everolimus in TSC and immunosuppressive therapies in autoimmune encephalitis. Screening for comorbidities was routinely done, but specific treatment protocols were lacking in most centers. / Significance: The survey summarizes the current clinical practice for selected rare epilepsies in tertiary European epilepsy centers and demonstrates consistency as well as heterogeneity in the treatment, underscoring the need for controlled trials and recommendations. The survey also provides estimates for potential participants of clinical trials recruited via EpiCARE, emphasizing the great potential of Reference Networks for future studies to evaluate new targeted therapies and to identify novel biomarkers

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version "Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)". The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility

XLIV Konferencja Komitetu Nauk o Żywności i Żywieniu PAN: nauka, technologia i innowacje w żywności i żywieniu

Streszczenia w jęz. angielskimWydarzenie: XLIV Konferencja Komitetu Nauk o Żywności i Żywieniu PAN; Łódź, 3-4 lipca 2019 r.; http://pan.binoz.p.lodz.plOrganizator konferencji: Wydział Biotechnologii i Nauk o Żywności PŁ; Komitet Nauk o Żywności i Żywieniu PAN; Polskie Towarzystwo Technologów ŻywnościProjekt graficzny okładki: Grzelczyk, J.Projekt graficzny okładki: Klewicki, R.Skład: Oracz, J.Za treść zamieszczonych materiałów odpowiadają ich autorzy.Sesje Naukowe Komitetu Nauk o Żywności i Żywieniu Polskiej Akademii Nauk (KNoŻiŻ PAN) są organizowane przez krajowe ośrodki akademickie związane z naukami o żywności i żywieniu w dwuletnich cyklach. Sesje te stanowią największe w skali kraju forum prezentacji najnowszych osiągnięć naukowych i technologicznych w dziedzinie technologii żywności i żywienia człowieka, jak również wymiany poglądów oraz doświadczeń pracowników jednostek naukowych i przedstawicieli przemysłu spożywczego. Tematyka XLIV Sesji dotyczyć będzie szeroko pojętej problematyki związanej z oddziaływaniem żywności i odżywiania na zdrowie człowieka